Could Wegovy Raise Optic Nerve Risk? - Top-Institutions - MDSpire

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

  • By

  • Kerri Miller

  • March 11, 2026

  • 5 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Pharmacovigilance

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Clinical Epidemiology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Pharmacovigilance

  • #4

    University of Ottawa Faculty of Medicine
    University of Ottawa Faculty of Medicine

    Ottawa, ON

    Key Differentiators

    • Ophthalmology
    • Pharmacovigilance
    • Clinical Research

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Pharmacovigilance

Original Source(s)

Could Wegovy Raise Optic Nerve Risk?

  • by Kerri Miller

  • March 11, 2026

Related Content

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

New Strategies for Managing Diabetic Retinopathy